Seattle Cancer Care Alliance (SCCA) is recruiting patients with prostate cancer to participate in a new registry called PROMISE — Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness. The PROMISE registry will help researchers learn more about how germline mutations affect prostate cancer outcomes.
Heather Cheng, MD, PhD, director of Seattle Cancer Care Alliance (SCCA) Prostate Cancer Genetics Clinic, is a principal investigator for PROMISE. A leading expert in inherited genetics of prostate cancer risk, Dr. Cheng uses genomics to drive precision-based prostate cancer treatment.
“In PROMISE, we’re following patients receiving all types of treatments,” says Dr. Cheng. “Over time, this will help us figure out why some patients respond and others don’t and identify patterns associated with the best responses.”
The PROMISE registry offers:
PROMISE builds upon pioneering prostate cancer genetics research at SCCA, Fred Hutch and UW Medicine. In a landmark study published in 2016 in the New England Journal of Medicine, UW Medicine researchers, including Dr. Cheng, identified germline mutations in 11.8% of men with metastatic prostate cancer.
These mutations included BRCA1, BRCA2 and others, including some that are also connected with inherited breast and ovarian cancers. Identifying genetic mutations in patients has significant treatment implications since drugs can target cellular processes in these types of cancer.
The 2016 study and others prompted the National Comprehensive Cancer Network (NCCN) to update its prostate cancer guidelines in 2019. The current guidelines recommend genetic testing for all men with metastatic, high-risk localized and node-positive prostate cancer. But PROMISE goes beyond that, says Dr. Cheng.
“PROMISE extends beyond these high-risk groups and hypothesizes that genetic testing is important for all men with prostate cancer,” she says. “We know that some men with low-risk disease have genetic mutations, but we don’t know how many. It may be a smaller fraction, but it is no less important, especially for the family members who may also be impacted.”
The goals of PROMISE are two-fold. The first is to offer free virtual genetic testing and counseling. This benefits patients who:
The second goal is to follow patients with known germline mutations long-term to determine clinical and treatment outcomes. “We are also very interested in recruiting individuals with prostate cancer who have an inherited cancer risk mutation, ,” says Dr. Cheng. “By participating, they will help us better understand current treatment modalities and patient outcomes. We hope to give that learning back to them and their families.”
Patient registration began in 2021 and will continue through 2026. Researchers will follow patients for at least 15 years.
Dr. Cheng and her colleagues will recruit approximately 5,000 men with prostate cancer for germline genetic screening to identify:
Eligibility criteria to participate in PROMISE include:
Patients can sign up for PROMISE on the study’s dedicated website www.prostatecancerpromise.org. After signing up, they receive a home saliva test kit to return by mail. Patients and their physicians receive results through the PROMISE portal in four to eight weeks.
Patients who receive a positive test result meet virtually with a PROMISE genetic counselor. This visit focuses on what the results mean and how the genetic mutation may impact the patient and their family. Patients with negative test results also have the option to schedule a genetic counseling visit.
Patients with certain genetic mutations become part of the registry. The test kit screens for 30 cancer risk genes, such as:
Researchers use patient data to assess the association between germline mutations and disease characteristics. The PROMISE team collects patient data every six months through:
Participating patients and their physicians receive regular newsletters with updated information about:
PROMISE comes at a time of rapid advancement in therapies that target inherited cancers. For example, PARP inhibitors and immune checkpoint inhibitors target cancers with specific gene mutations. Though these drugs can be very effective, many patients eventually develop resistance.
Current clinical trials are looking at combined therapies to increase the effectiveness of these drugs without side effects. By tracking patients long-term, PROMISE will help Dr. Cheng and her colleagues evaluate how patients respond to various therapies and identify the most therapeutic combinations.
Dr. Cheng and Dr. Channing Paller, MD, of Johns Hopkins Medicine, are leading PROMISE in partnership with Advancing Cancer Treatment (ACT) and the Prostate Cancer Clinical Trials Consortium (PCCTC).
PROMISE is open to patients nationwide. To find out more, visit the PROMISE registry website at www.prostatecancerpromise.org